Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Final results of the BFORE trial: bosutinib vs imatinib in CP-CML

Michael Deininger • 21 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia Bosutinib Imatinib
BFORE

Michael Deininger, MD, PhD, The Medical College of Wisconsin, Milwaukee, WI, gives an overview of the final results of the BFORE trial (NCT02130557) which compared imatinib versus bosutinib in patients with chronic phase chronic myeloid leukemia (CP-CML). Overall, the BFORE trial demonstrated the superiority of bosutinib over imatinib in terms of depth of response and toxicity, but did not show a difference in overall survival (OS). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Novartis, BMS, Incyte, Takeda, Blueprint, Cogent, CTI.

More from Michael Deininger

1:24
Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates
Michael Deininger • 21 Oct 2022
1:09
Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML
Michael Deininger • 21 Oct 2022
1:33
ESH CML workshop highlights: 3D genomics and nuclear organization
Michael Deininger • 21 Oct 2022
1:37
OPTIC: Ponatinib in chronic-phase CML
Michael Deininger • 12 Dec 2021

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals